ArticleCell biology and toxicology2026
The HDAC1 inhibitor attenuates renal ischemia-reperfusion injury via dual epigenetic modulation of p53 and macrophage NF-κB pathways.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe renal regenerative capacity hinges on tubular epithelial cell (TEC) plasticity, while Macrophage activation and their crosstalk with tubular cells further drive ischemia-reperfusion injury (IRI) progression, where epigenetic regulation critically directs cellular fate. Based on the established association between HDAC dysregulation-specifically HDAC1-and renal injury, we investigated the therapeutic strategies and and epigenetic regulatory mechanisms underlying mechanisms of the selective HDAC1 inhibitor FK228 in renal IRI.
methodsThis study employed IRI animal models, along with in vitro culture systems of TECs and bone marrow-derived macrophages (BMDMs). A range of immunological and molecular biology techniques was used to assess TEC apoptosis and repair, as well as macrophage migration and polarization, with key molecular changes and their interactions visualized, too.
resultsOur findings demonstrate that FK228 confers renoprotection in renal IRI through HDAC1-dependent modulation of p53 activity, coordinating the regulation of apoptotic pathways (P53-Caspase-3) and proliferative responses in tubular epithelium while attenuating oxidative stress and modulating macrophage crosstalk. And beyond that, FK228 delays IRI progression and fibrosis by inhibiting the HDAC1-HIF-1α-NF-κB signaling axis, thereby suppressing morphological transformation and limiting macrophage proliferation and differentiation. Confocal microscopy revealed that FK228 redistributes phosphorylated NF-κB p65 and HIF-1α to the cytoplasm while reducing their nuclear co-localization.
conclusionIn conclusion, This study demonstrates that FK228 protects TECs from IRI by modulating the p53-Caspase-3/Bcl-2 pathway to inhibit apoptosis. Additionally, FK228 targets the HDAC1-HIF-1α-NF-κB axis to suppress pathological macrophage polarization, thereby delaying renal fibrosis and ameliorating both acute injury and its chronic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.